SEATTLE, July 2018 – Pacific Biomarkers, a premier biomarker laboratory services provider based in Seattle, announced the appointment of Dr. Cheikh Kane to the position of Director of Bioanalytical Services.
Pacific Biomarkers maintains a “fit-for-purpose” assay development and validation philosophy that spans feasibility to full validations using CAP, CSLI or FDA/EMA bioanalytical guidelines to match the intended use of a sponsor’s drug in development. “Our validation work includes all novel biomarkers, technology transfers and bioanalytical work associated with a biologic drug where PK, ADA and immunogenicity assays are required”, stated Dr. Amar A. Sethi, President and Chief Scientific Officer, Pacific Biomarkers. Dr. Sethi continued, “It is in keeping with this vision that we are pleased to have Dr. Kane join our organization.” Dr. Kane brings with him 15 years of Immunoassay experience for large molecules, regulatory knowledge, and extensive problem-solving skills in the immunogenicity assay development area. In his role as Director of Bioanalytical Services, Dr. Kane manages the bioanalytical laboratory and provides scientific leadership and technical support to the Company’s testing services. Prior to joining Pacific Biomarkers, Dr. Kane served as Principal Scientist and Group leader at Boehringer Ingelheim-US. Prior to that position, he was a Senior Research Scientist in the Immunogenicity group at Charles River Laboratories in Canada. Dr. Kane earned a PhD in Virology (Microbiology)-Immunology from National Institute of Scientific Research (INRS), Canada.
Pacific Biomarkers is a CAP accredited and CLIA certified biomarker laboratory services provider supporting preclinical and Phase I-IV studies. Since 1989, Pacific Biomarkers has partnered with the Pharmaceutical, Biotech and Diagnostic Manufacturing Industries to provide biomarker laboratory services. Pacific Biomarkers has an established reputation for being on the leading edge of biomarker innovation and provides clients with the best available biomarker testing to produce strong analytical data that meets regulatory compliance and quality assurance standards. Pacific Biomarkers’ customized approach which combines scientific consultation, flexibility, and outstanding client services has propelled the company to a prominent position in the rapidly growing pharmaceutical outsourcing industry. With a well-established network of scientific, regulatory, and technology expertise, Pacific Biomarkers is the service provider of choice for many leading international drug manufacturers in the race to bring products to market as quickly and cost effectively as possible.
Amar A. Sethi, MD, PhD
President and Chief Scientific Officer